🧬 Amylin & GLP-1: Double Agents for Weight Loss & DM-CagriSema (Part II)

🚨 Major breakthrough in obesity pharmacotherapy! The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉 🌍 Global, double-blind RCTs ⚖️ >90% lost ≥5% body weight 🩺 SBP ↓, QoL ↑, prediabetes reversed in 88% ⚠️ GI side effects common but mostly mild 💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.   #Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine